kennedy glp 1 Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too Can RFK Jr. Limit Ozempic

Description

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

High-profile celebrities have publicly discussed using GLP-1 receptor agonists for weight management, sparking global interest in semaglutide and tirzepatide

Introduced in the twenty-first century, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits

Feel the Difference - Naturally

Glucagon-like peptide-1 receptor agonists show promise for reducing apnea-hypopnea index and body weight in patients with obstructive sleep apnea, offering new treatment options beyond PAP therapy.